Oscient granted the commercialization rights for Factive to Abbott Canada in August of last year. Oscient received a modest milestone payment from Abbott Canada related to the launch.
“As the most active member of the fluoroquinolone class of antibiotics in vitro, Factive is an important addition to our anti-infective product portfolio,” stated Marcelo Vizio, general manager, Abbott Canada, Abbott International.
“We are marketing Factive, with its convenient once-daily dosing and short-course therapy, to physicians across Canada with our primary care sales force.”
In 2004, Factive was approved in Canada for the treatment of acute bacterial exacerbations of chronic bronchitis (AECB). Abbott Canada plans to pursue additional indications for Factive in the future and has access to the drug’s entire clinical trial dossier.